# Novartis (NVS) — News

NVS · NYSE · Stock

Canonical page: https://www.lighthorse.io/tickers/nvs/news

## Recent headlines

- [Lakefront announces sale of preclinical CAR-T programs to Armed Cell Therapeutics](https://www.ainvest.com/news/lakefront-announces-sale-preclinical-car-programs-armed-cell-therapeutics-2610) — AInvest Wire, Oct 14, 2026
  Lakefront Therapeutics has announced the sale of its preclinical CAR-T cell therapy programs to Armed Cell Therapeutics, a move that reflects ongoing strategic realignments within the biotechnology sector. The transaction, which includes intellectual property and research assets, is expected to…
- [New deal: Atlas Warehouse lending $Bmark 6NCS +150 area](https://www.ainvest.com/news/deal-atlas-warehouse-lending-bmark-6ncs-150-area-2610) — AInvest Wire, Oct 14, 2026
- [Novartis India approves raising upto 9B rupees via rights issue](https://www.ainvest.com/news/novartis-india-approves-raising-upto-9b-rupees-rights-issue-2610) — AInvest Wire, Oct 8, 2026
  Novartis India Limited, now rebranded as Evonile Pharma Limited, has announced plans to raise up to 9 billion rupees through a rights issue. This move follows a series of strategic developments, including the company’s recent corporate rebranding and the acquisition of a majority stake by…
- [Isomorphic Labs in funding talks for at least $40 billion value](https://www.ainvest.com/news/isomorphic-labs-funding-talks-40-billion-2610) — AInvest Wire, Oct 8, 2026
  Isomorphic Labs, an artificial intelligence-driven drug discovery company, has attracted significant investor interest, with recent reports suggesting the firm is in funding discussions that could value the company at $40 billion or more. This potential valuation would represent a substantial…
- [Novartis AG - Rhapsido safety profile in SD consistent with CSU; no routine lab monitoring required](https://www.ainvest.com/news/novartis-ag-rhapsido-safety-profile-sd-consistent-csu-routine-lab-monitoring-required-2610) — AInvest Wire, Oct 7, 2026
  Novartis AG has reported that the safety profile of Rhapsido in patients with chronic spontaneous urticaria (CSU) is consistent with its known characteristics. The company emphasized that routine laboratory monitoring is not required for patients receiving the treatment, based on findings from its…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).